Patents Assigned to The United States of America as represented by the Department of of Health and Human Services
  • Patent number: 7951786
    Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: May 31, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihsan Gursel, Mayda Gursel
  • Patent number: 7951383
    Abstract: The invention provides isolated nucleic acids encoding recombinant genomes or antigenomes of Human Parainfluenza Viruses that are useful as vaccines. The recombinant genomes or antigenomes can be incorporated into expression vectors for production of recombinant viruses in vitro. The invention also provides recombinant Human Parainfluenza viruses having one or more mutations that attenuate replication of the virus in a host.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: May 31, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. Murphy, Peter L. Collins, Mario H. Skiadopoulos
  • Patent number: 7951817
    Abstract: Compounds represented by the formula: wherein R is C1-6 alkyl; C4-6 cycloalkylalkyl; or C3-6 alkenyl; R? is H or C1-6 alkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to ? agonists.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 31, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, Southern Research Institute, University of New England College of Osteopathic Medicine, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Subramaniam Ananthan, Richard B. Rothman, Edward J. Bilsky, Frank Porreca
  • Patent number: 7947651
    Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: May 24, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, University of Massachusetts
    Inventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren
  • Patent number: 7947503
    Abstract: A dust monitor is disclosed that is suitably deployed in dusty environments and capable of providing near real-time indications of exposure to airborne particulates. The monitor includes a filter and filter assembly made of materials that do not interfere with subsequent instrumental (such as spectrometric) analysis for detecting and/or quantitating an analyte. In some disclosed embodiments, the filter is made of nylon or other material that is readily subjected to thermal destruction prior to spectrometric analysis. The dust monitor also includes a humidity correction feature that permits the filter to be made of ashable organic materials even if those materials are not highly hydrophobic. Transport devices are provided for shipment of the filter and/or filter assembly to an analytical laboratory which prevent loss of particulate matter and which facilitate an accurate analysis procedure.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: May 24, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Donald P. Tuchman
  • Patent number: 7947822
    Abstract: The invention provides a composition comprising a pharmaceutically acceptable carrier and six plasmids, each of which encodes an HIV Env, Gag, Pol, or Nef protein. The invention also provides a method of inducing an immune response in an animal using the composition.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: May 24, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gary J. Nabel, Bimal Chakrabarti, Wing-Pui Kong, Yue Huang, Zengguang Wang, legal representative, Zhi-Yong Yang
  • Patent number: 7939635
    Abstract: The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: May 10, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Mary Stracke, Lance Liotta, Elliott Schiffmann, Henry Krutzch, Jun Murata
  • Patent number: 7935351
    Abstract: This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: May 3, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, University of Tennessee Research Foundation
    Inventors: Dennis M. Klinman, Mei Zheng, Barry T. Rouse
  • Patent number: 7932721
    Abstract: An apparatus for imaging includes: a radio frequency (RF) coil array having a first RF coil and at least one additional RF coil, where the RF coil array is adapted to generate an image signal; a preamplifier having an input impedance, where the preamplifier is adapted to receive the image signal from the first RF coil; and a transformer to couple the first RF coil to the preamplifier, where impedance of the transformer is adapted to match the input impedance of the preamplifier.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: April 26, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: George Nascimento, Afonso C. Silva
  • Patent number: 7932074
    Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: April 26, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Albert Z. Kapikian, Robert M. Chanock, Yasutaka Hoshino
  • Patent number: 7933721
    Abstract: Clinical samples can be analyzed using microparticles to determine the serodiagnosis of a viral infection from two candidate viral infections of the same viral group. Serodiagnosis can be determined via a pooled population of subsets of microparticles, with the particles in the pooled population having a bound viral group-reactive antibody and the particles in each subset having at least one characteristic classification parameter that distinguishes between subsets. Viral antigens of antibodies of interest in the same viral-class as the viral group-reactive antibody can be bound to the viral group-reactive antibody on the microparticles, and subsequently exposed to a clinical sample. Binding and labeling can be used. Automated analysis of data from multiplexed flow analysis can determine the presence or absence of antibodies of interest in the sample, thereby diagnosing for two candidate viral infections in a single assay.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: April 26, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Alison Jane Johnson, Bradley John Biggerstaff
  • Patent number: 7927793
    Abstract: Host nucleic acids and host proteins that participate in viral infection, such as human immunodeficiency virus (HIV), influenza A, and Ebola virus, have been identified. Interfering with or disrupting the interaction between a host nucleic acid or host protein and a virus or viral protein confers an inhibition of or resistance to infection. Thus, interfering with such an interaction in a host subject can confer a therapeutic or prophylactic effect against a virus. The sequences identified can be used to identify agents that reduce or inhibit viral infection.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: April 19, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, Vanderbilt University
    Inventors: Thomas W. Hodge, Natalie J. McDonald, Michael W. Shaw, Donald H. Rubin, Anthony Sanchez
  • Patent number: 7924425
    Abstract: A system for spatially selective, fixed-optics fluorescence detection in a multichannel polymeric microfluidic device, and a method for performing spatially selective, fixed-optics fluorescence detection.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: April 12, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicole Y. Morgan, Paul Smith, Ed Wellner
  • Patent number: 7919104
    Abstract: Provided is a P4 peptide, which contains functional epitopes of the PsaA protein of Streptococcus pneumoniae, and related methods and compositions. P4 peptide mimetics having a conformational structure identical or similar to the conformation of P4 (e.g., SEQ ID NO: 1 and SEQ ID NO:2) are provided. An antibody that specifically binds to the epitope defined by the disclosed peptides is provided. A P4-specific antibody is PsaA-specific since P4 defines an epitope specific for PsaA. Immunogenic compositions comprising the peptide of SEQ ID NO: 1 and a pharmaceutical carrier or the peptide of SEQ ID NO:2 and a pharmaceutical carrier are also provided. Methods of using the peptides and antibodies of the invention are provided.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: April 5, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Edwin W. Ades, Jacquelyn S. Sampson, Sandra Steiner, George M. Carlone, Joseph J. Caba, GowriSankar Rajam
  • Patent number: 7919607
    Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: April 5, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
  • Patent number: 7919477
    Abstract: Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: April 5, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis Klinman, Ken Ishii, Daniela Verthelyi
  • Patent number: 7914788
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: March 29, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
  • Patent number: 7910105
    Abstract: The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: March 22, 2011
    Assignees: Wyeth LLC, The United States of America as represented by the Department of Health and Human Services, President and Fellows of Harvard College
    Inventors: Deborah A. Young, Thomas A. Wynn, Mary Collins, Michael J. Grusby
  • Patent number: 7910692
    Abstract: The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: March 22, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang, Ira H Pastan
  • Patent number: 7906283
    Abstract: The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 15, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, Board of Regents, the University of Texas System
    Inventors: Francis J. McMahon, Gonzalo E. Laje, Silvia Paddock, Husseini K. Manji, A. John Rush